Table II.
Factors correlated with survival in patients receiving surgery followed by oxaliplatin-based adjuvant chemotherapy.
| n | M-RFS (months) | P-value | MST (months) | P-value | |
|---|---|---|---|---|---|
| Gender | 0.526 | 0.408 | |||
| Male | 37 | 14 | 24 | ||
| Female | 15 | 9 | 21 | ||
| Age (years) | 0.017 | 0.019 | |||
| ≤58 | 25 | 8 | 15 | ||
| >58 | 27 | 18 | |||
| Tumor differentiation | 0.652 | 0.419 | |||
| Well | 20 | 17 | 22 | ||
| Moderate | 25 | 12 | 22 | ||
| Undifferentiated | 7 | 8 | 15 | ||
| Tumor location | 0.484 | 0.598 | |||
| Proximal stomach | 14 | 10 | 17 | ||
| Stomach body | 10 | 13 | 21 | ||
| Distal stomach | 28 | 16 | 24 | ||
| Staging | <0.001 | <0.001 | |||
| I, II and III | 32 | 18 | |||
| IV | 20 | 6 | 11 | ||
| ERCC1 level | 0.001 | 0.001 | |||
| <7.32 | 29 | 18 | 27 | ||
| ≥7.32 | 23 | 7 | 12 | ||
| Carcinoembryonic antigen (ng/ml) | <0.001 | <0.001 | |||
| ≤5 | 33 | 18 | 27 | ||
| >5 | 19 | 6 | 12 |
ERCC1, excision repair cross-complementation group 1; M-RFS, median relapse-free survival; MST, median survival time.